Used as a key intermediate in the synthesis of targeted protein degradation therapeutics, particularly in the development of cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, facilitating the degradation of disease-related proteins. This makes it valuable in research for anticancer drugs, especially in hematological malignancies like multiple myeloma. It is also employed in the creation of PROTACs (proteolysis-targeting chimeras), where it serves as the E3 ligase recruiting moiety. Due to its bromo functional group, it allows for further chemical modifications through cross-coupling reactions, enhancing its utility in medicinal chemistry and drug discovery.